UroGen Pharma
URGN
92 hedge funds and large institutions have $237M invested in UroGen Pharma in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 5 closing their positions.
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
12% more funds holding
Funds holding: 82 → 92 (+10)
11% more capital invested
Capital invested by funds: $214M → $237M (+$23.4M)
4% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 24
2% more call options, than puts
Call options by funds: $1.46M | Put options by funds: $1.44M
0.24% more ownership
Funds ownership: 62.75% → 63% (+0.24%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$13.6M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.9M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$1.82M |
| 4 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$1.19M |
| 5 |
HCM
Horton Capital Management
Philadelphia,
Pennsylvania
|
+$898K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$17M |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$5.8M |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$1.46M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$1.14M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$842K |
URGN Hedge Fund Activity: Q3 2021 in Review
92 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q3 2021, worth a combined $237M — up 11% from $214M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new URGN positions and 5 closed out — a net gain of 10 holders — while 25 added to existing stakes and 24 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $13.6M. The largest seller was Wellington Management Group, cutting an estimated $17M.
- 92 institutional investors held UroGen Pharma (URGN) as of Q3 2021, up from 82 in Q2 2021.
- Funds reported $237M of UroGen Pharma stock for Q3 2021, up 11% quarter-over-quarter.
- 15 funds opened new UroGen Pharma positions in Q3 2021 and 5 closed out, a net change of +10 holders.
- The largest UroGen Pharma buyer in Q3 2021 was RTW Investments, an estimated $13.6M added.
- The largest UroGen Pharma seller in Q3 2021 was Wellington Management Group, an estimated $17M sold.
Based on aggregated 13F filings for Q3 2021.